证券代码：300012 证券简称：华测检测 公告编号：2025-029 华测检测认证集团股份有限公司 第六届董事会第二十四次会议决议公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 华测检测认证集团股份有限公司（以下简称"公司"）第六届董事会第二十 四次会议于 2025 年 6 月 20 日发出会议通知，2025 年 6 月 23 日以现场结合通讯方 式召开。本次会议应参与董事 7 名，实际参与董事 7 名，分别为：万峰、申屠献 忠、钱峰、戚观成、曾繁礼、程海晋、刘志权。会议由董事长万峰主持，董事会 会议的举行和召开符合国家有关法律、法规及《公司章程》的规定。经充分讨论 和审议，会议形成决议如下： 一、会议以 7 票同意、0 票反对、0 票弃权，审议通过了《关于首期员工持股计划 延期的议案》 基于目前证券市场的情况，综合考虑公司实际发展状况，切实发挥员工持股 计划的激励作用，公司拟将首期员工持股计划存续期延长至 2027 年 12 月 31 日。 本次员工持股计划可以在延长期内出售股票，在存续期内，若员工持股计划所持 有的公司股票全部出售，员工持股计划可提前 ...

Group 1 - The CRO concept sector experienced a decline of 1.65%, ranking among the top declines in the concept sector, with notable declines from companies such as Saint Noble Bio, Meinohua, and Ruizhi Medicine [1][2] - Among the CRO concept stocks, 10 stocks saw price increases, with Wanbang Pharmaceutical, Puni Testing, and Huace Testing leading the gains at 6.96%, 3.37%, and 2.25% respectively [1][2] - The CRO concept sector faced a net outflow of 1.109 billion yuan in main funds, with 48 stocks experiencing net outflows, and 6 stocks seeing outflows exceeding 50 million yuan [2][3] Group 2 - The top net outflow stock was WuXi AppTec, with a net outflow of 337 million yuan, followed by Lianhua Technology, Ruizhi Medicine, and Kailai Ying with net outflows of 136 million yuan, 105 million yuan, and 86 million yuan respectively [2][3] - The stocks with the highest net inflow included Huace Testing, Dongcheng Pharmaceutical, and Jinshi Yao, with net inflows of 29.24 million yuan, 23.51 million yuan, and 15.25 million yuan respectively [2][4] - The overall market sentiment reflected a mixed performance across various concept sectors, with brain-computer interface leading the gains at 6.63% while the CRO concept lagged behind [2][4]

Group 1 - Over 200 foreign institutions have conducted research on A-share listed companies since May, totaling more than 500 investigations, with a focus on hard technology sectors such as electronic devices and integrated circuits [1] - Notable foreign institutions involved in the research include Goldman Sachs, Fidelity, BlackRock, UBS, Allianz, and Point72, with companies like Aopu Technology, Lanke Technology, Hudian Co., and Aobi Zhongguang attracting over 30 foreign institution investigations each [1] - Point72, referred to as "Wall Street's craziest money-making machine," led the research activities with 17 investigations, focusing on companies such as Huace Testing, Miaoke Landuo, and Ruixin Micro [1] Group 2 - In addition to electronic devices and integrated circuits, sectors such as healthcare, industrial machinery, and electronic components have also garnered significant attention from foreign institutions, with industry leaders like BeiGene, Huichuan Technology, New Industry, and Shenzhen South Circuit receiving the most investigations [2] - Multiple foreign giants believe that the A-share market presents abundant investment opportunities, particularly in the technology growth sector, with Morgan Stanley highlighting key areas such as technology growth, Chinese manufacturing, and new consumption as worthy of attention [3] - Morgan Asset Management is optimistic about sectors including leading automotive manufacturers and components, AI-related industries, robotics, trendy toys, and pet-related businesses [3]

近5日机构合计调研302家公司，肇民科技、中微公司、华测检测等被多家机构扎堆调研。 证券时报·数据宝统计，近5个交易日（5月27日至6月3日）两市约302家公司被机构调研，调研机构类型 显示，证券公司共对272家公司进行调研，即90.07%的上市公司调研活动有证券公司参与；基金公司调 研232家，位列其后；阳光私募机构调研119家，排名第三。 机构调研榜单中，共有69家公司获20家以上机构扎堆调研。肇民科技最受关注，参与调研的机构达到 281家；中微公司被212家机构调研，榜单中排名第二；华测检测、拓荆科技等分别被187家、179家机构 调研。 机构调研次数来看，三友联众机构调研最为密集，共获机构4次调研。能辉科技、周大生等机构调研也 较为密集，均被机构调研3次。 数据宝统计，20家以上机构扎堆调研股中，近5日资金净流入的有24只，中科金财近5日净流入资金4.04 亿元，主力资金净流入最多；净流入资金较多的还有海大集团、北特科技等，净流入资金分别为2.46亿 元、1.27亿元。 市场表现上，机构扎堆调研股中，近5日上涨的有27只，涨幅居前的有华纳药厂、科兴制药、益方生物 等，涨幅为64.66%、53.29%、 ...

Group 1: Investor Relations Activities - The company conducted a series of investor relations activities from March 4 to May 30, 2025, including online meetings and on-site research, involving a total of 10 to 40 participants per event [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25]. Group 2: Business Development in High-Tech Fields - The company has strategically invested in high-tech and emerging technology sectors, focusing on AI, humanoid robots, and low-altitude economy, enhancing its service offerings in these areas [6][7]. - In the automotive sector, particularly in new energy vehicles, the company has established deep collaborations with numerous manufacturers, ensuring safety and reliability in vehicle testing [9][10]. Group 3: Digital Financial Technology - The company has developed a three-dimensional testing system for digital financial technology products, achieving national-level testing qualifications for client-side and embedded software [8]. - Recent acquisitions have strengthened the company's position in the cybersecurity assessment market, expanding its service capabilities across multiple regions [8]. Group 4: Semiconductor and Chip Industry - The company remains optimistic about the long-term potential of the semiconductor industry, actively pursuing transformation and investment in key areas such as FA and MA [11]. - The company has optimized its management team and is focusing on enhancing operational capabilities to adapt to market changes [11]. Group 5: Pharmaceutical and Medical Sector - The pharmaceutical sector has shown signs of recovery after a period of adjustment, with a focus on high-value areas and stable client relationships [12][13]. - The company has completed the construction of comprehensive testing capabilities for medical devices, ensuring steady growth in revenue and profit [12][13]. Group 6: Future Revenue and Profit Growth - The company has maintained a strategic focus on long-term growth despite economic challenges, implementing a "123 strategy" to enhance operational efficiency and market positioning [14][22]. - The company plans to optimize resource allocation to create a balanced portfolio of cash flow, high-growth, and future reserve businesses [14]. Group 7: Mergers and Acquisitions Strategy - The company is actively pursuing strategic mergers and acquisitions to enhance its international competitiveness, focusing on sectors such as consumer goods and transportation [15][18]. - Recent acquisitions include the purchase of ALS Group's subsidiary in China, aimed at expanding capabilities in geochemical testing [19][20]. Group 8: Shareholder Returns and Dividends - The company has implemented a cash dividend policy, distributing RMB 1 per 10 shares to shareholders, with a historical payout ratio of 64.01% over the past three years [21]. - The board is considering increasing mid-term cash dividends to enhance shareholder returns [21]. Group 9: Strategic Resilience Amid Uncertainty - The company is committed to maintaining strategic stability in the face of external uncertainties, focusing on lean management and operational excellence [22][23]. - Plans include the integration of AI technologies to improve efficiency and service quality across various business segments [23][24].

Investment Rating - The report maintains an "Overweight" rating for the mechanical equipment industry [1]. Core Insights - The mechanical equipment industry is experiencing an upward trend, particularly in construction machinery, with a notable recovery in excavator sales and a shift in demand towards non-excavator machinery [2][3]. - The humanoid robot sector is advancing, with Tesla's Optimus showcasing enhanced learning capabilities, which could accelerate commercialization [2]. - The forklift market is seeing mixed performance, with domestic sales declining slightly while exports are growing, driven by increased lithium battery penetration [3]. Summary by Sections Recommended Stocks - The report suggests a focus on companies such as Northern Huachuang, Sany Heavy Industry, and others across various segments including humanoid robots, engineering machinery, and forklifts [1][12]. Engineering Machinery - Excavator sales have shown a recovery, with April 2025 figures indicating a year-on-year increase of 18% [2]. - The demand for road machinery is on the rise, with significant growth in sales of rollers and pavers [2]. - The report highlights the importance of overseas markets, particularly in Southeast Asia and Africa, for future growth in engineering machinery exports [15][17]. Forklift Market - In April 2025, forklift sales reached 130,000 units, with exports increasing by 18% while domestic sales fell by 1% [3]. - The report notes that domestic manufacturing sentiment is weak, impacting local sales, but the export market remains robust due to improved overseas distribution channels [3]. Humanoid Robots - The report emphasizes the importance of generalization capabilities in humanoid robots, with Tesla's Optimus demonstrating significant advancements in skill acquisition [2]. - The application of humanoid robots in logistics and other sectors is becoming increasingly essential, indicating a growing market demand [2]. General Automation - The industrial automation sector is showing signs of recovery, with specific recommendations for companies like Estun and others in the FA automation space [28]. - The report notes that the injection molding machine market is maturing domestically, with significant potential for overseas expansion [29]. Detection Services - The detection services sector is expected to benefit from government stimulus and a recovery in domestic demand, with leading companies like Huace Detection showing resilience [34][36].

Core Viewpoint - The company has announced its 2024 annual profit distribution plan, which includes a cash dividend of RMB 1 per 10 shares and no bonus shares, approved by the shareholders' meeting held on May 19, 2025 [1][2][3]. Summary by Sections Shareholders Meeting Approval - The profit distribution plan was approved during the 2024 annual shareholders' meeting, with a cash dividend of RMB 1 per 10 shares (including tax) and no bonus shares [1][2]. Profit Distribution Plan - The total share capital for the distribution is 1,672,828,214 shares after excluding 10,000,000 repurchased shares. The total cash dividend amount is calculated to be RMB 167,282,821.40 [4][8]. Dividend Payment Details - The cash dividends will be directly credited to shareholders' accounts on May 28, 2025, through their respective securities companies [7]. - Different tax rates apply for various categories of shareholders, with specific provisions for Hong Kong investors and domestic investors [4][8]. Record and Ex-Dividend Dates - The record date for the dividend distribution is set for May 27, 2025, and the ex-dividend date is May 28, 2025 [4][5]. Calculation of Dividend and Reference Price - The reference price for the ex-dividend will be adjusted based on the cash dividend distributed per share, calculated as RMB 0.0994057 per share [8].

Core Viewpoint - The company has announced its 2024 annual profit distribution plan, which includes a cash dividend of RMB 1 per 10 shares and no bonus shares, approved by the shareholders' meeting held on May 19, 2025 [1][2]. Summary by Sections 1. Profit Distribution Plan - The profit distribution plan involves a cash dividend of RMB 1 per 10 shares (including tax) for all shareholders, with no bonus shares distributed [1][2]. - The total amount for distribution will not exceed the distributable profits as per the financial statements, and adjustments will be made if the total share capital changes before implementation [1][2]. 2. Key Dates - The record date for the profit distribution is set for May 27, 2025, and the ex-dividend date is May 28, 2025 [2]. 3. Distribution Method - Cash dividends will be directly credited to shareholders' accounts through their custodial securities companies on the ex-dividend date [3]. 4. Calculation of Dividend - The actual cash dividend amount is calculated based on the total share capital minus repurchased shares, resulting in a cash dividend of approximately RMB 0.994057 per 10 shares [4]. - The reference price for the ex-dividend will be adjusted based on the cash dividend amount and the total share capital on the record date [4]. 5. Consultation Information - The company provides contact details for inquiries regarding the profit distribution plan, including a contact person and phone numbers [3].

证券代码：300012 证券简称：华测检测 公告编号：2025-028 华测检测认证集团股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 华测检测认证集团股份有限公司（以下简称"公司"）2024 年年度权益分 派方案已获 2025 年 5 月 19 日召开的 2024 年度股东大会审议通过，现将权益分 派事宜公告如下： 一、股东大会审议通过权益分派方案情况 1、公司 2024 年度股东大会审议通过分配方案的具体内容：以公司实施利润 分配方案时股权登记日可参与利润分配的总股本为基数，向全体股东每 10 股派 发现金股利人民币 1 元（含税），送红股 0 股，以资本公积金向全体股东每 10 股转增 0 股。本次利润分配预案公布后至实施前，如公司参与分红总股本由于股 份回购、股权激励、员工持股计划等原因而发生变化时，按照分配比例不变的原 则，以未来实施本次分配预案时股权登记日参与分红的公司总股本为基数进行利 润分配，分红金额总额相应调整，公司预计分配总额不会超过财务报表上可供分 配利润。 现金（含税；扣税后，通过深股通持 ...

Investment Rating - The report suggests a focus on leading companies with strong management and brand recognition in the testing service industry, particularly recommending companies like Huace Testing, Sutest, and Guangdian Measurement [6][13][44]. Core Viewpoints - The testing service sector is under pressure, with a focus on lean management and the expansion of emerging industries. The overall revenue for the sector in 2024 is projected to be 46.8 billion RMB, a decrease of 4% year-on-year, primarily due to macroeconomic slowdowns and ongoing policy impacts in the pharmaceutical and special industries [4][18]. - The sector's growth is closely tied to macroeconomic performance, with expectations for recovery in demand due to government debt relief and stimulus policies [5][75]. - The industry is experiencing a trend towards consolidation, with resources expected to concentrate among leading firms that possess brand, capital, and management advantages [5][70]. Summary by Sections Revenue Performance - In 2024, the testing service sector achieved a revenue of 46.8 billion RMB, down 4% year-on-year. Excluding companies with high medical testing ratios, the sector's revenue was 25.8 billion RMB, showing a 4% increase year-on-year [4][18]. - The first quarter of 2024 saw a revenue of 9 billion RMB, a 9% decline year-on-year, but excluding high medical testing companies, the revenue growth rate improved to 2% [4][18]. Profitability - The sector's net profit for 2024 is expected to be 1.8 billion RMB, a significant decline of 56% year-on-year, attributed to decreased revenue, rigid laboratory costs, and reduced government subsidies [25]. - Leading companies like Huace Testing and Guangdian Measurement showed resilience, with net profit growth rates of 1% and 77% respectively in 2024 [25][18]. Market Trends - The global testing service market is projected to reach approximately 2.3 trillion RMB in 2024, with a compound annual growth rate (CAGR) of about 6% from 2021 to 2024. China's testing service industry has historically grown at about twice the GDP growth rate [5][58]. - The industry is characterized by a high degree of fragmentation, with small and weak players facing challenges in capital and management, leading to a trend towards consolidation [69][70]. Emerging Opportunities - New sectors such as semiconductors and low-altitude economy are developing rapidly, creating new demands for testing services that require significant capital and technical capabilities [6][70]. - The report emphasizes the importance of government policies in supporting the testing service industry, particularly through debt relief measures that could enhance demand recovery [75][86].